STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

Item

http://www.wikidata.org/entity/Q40819847

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

@en

type

Item

label

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

@en

prefLabel

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

@en

P1476

STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.

@en

P2093

A M Eiring

http://www.w3.org/2001/XMLSchema#string

B D Page

http://www.w3.org/2001/XMLSchema#string

I L Kraft

http://www.w3.org/2001/XMLSchema#string

M W Deininger

http://www.w3.org/2001/XMLSchema#string

P T Gunning

http://www.w3.org/2001/XMLSchema#string

T O'Hare

http://www.w3.org/2001/XMLSchema#string

P2860

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

P2888

leusup.2014.3

P304

S5-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEUSUP.2014.3

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049086911

http://www.w3.org/2001/XMLSchema#string

P698

27175272

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia

P932

4851281

http://www.w3.org/2001/XMLSchema#string